Spinal fluid test for Alzheimer’s raises interesting question

August 10, 2010

Today’s news of a new and accurate way of diagnosing Alzheimer’s disease through a spinal fluid test is both promising — and troubling.

Researchers writing for the Archives of Neurology told of a nearly 100-percent accurate test of cerebrospinal fluid for biomarkers that signal Alzheimer’s disease. The disease was confirmed in some of the study subjects through an examination of the brain after they died. What surprised the scientists was the presence of the Alzheimer’s disease signature in more than one-third of the cognitively normal subjects–suggesting that the disease “pathology is active and detectable earlier than has heretofore been envisioned,” the abstract says.

Dr. Steven DeKosky, dean of the University of Virginia medical school, told The New York Times “this is what everyone is looking for, the bull’s-eye of perfect predictive accuracy.”

Most experts believe that Alzheimer’s starts before symptoms become obvious, so having a way to identify victims early might lead to ways of slowing or preventing deterioration. Lots of drug studies are in various stages of experimentation and development for that purpose.

Here’s what’s a little troubling: Should doctors offer, and should patients accept, a test for a disease that has no treatment?

An accompanying editorial tackles this issue.

My thinking has always been that more information is better than less. However, as patients, we have to ask ourselves, what will we do with the information?

Say we are having memory troubles and fear Alzheimer’s. Would having such a test done (once it’s ready for prime time, that is) alleviate our fears? If the results said no, would it encourage our doctor to explore other causes? If the results said yes,  would knowing that make things worse for us–especially now, when there’s really not much that can help someone in the early stages of Alzheimer’s?

Maybe there will come a day when such a spinal fluid test would become something of a screening, like a mammogram to spot breast cancer or a colonoscopy to spot colorectal cancers. But we’re not there yet.

My other concern would be that a long term care insurance policy be firmly in place before the test. Because once someone is diagnosed with a dementia, good luck purchasing coverage. The costs of caring for someone with dementia are enormous. Without that coverage, I honestly don’t know how we would have cared for my father.

Read The New York Times article.

Read the abstract of the study.


Factors that may increase Alzheimer’s risk

June 1, 2010

Four factors are associated with an increased risk for Alzheimer’s disease and cognitive decline. They are not necessarily causes, but science has noticed some meaningful connection between these things and an increased risk for Alzheimer’s and cognitive decline. They are:

* diabetes,
* the gene variation ApoE,
* current smoking, and
* depression.

Evidence is not as strong for a connection between estrogens or nonsteroidal anti-inflammatory drugs and an increased risk for Alzheimer’s, and there’s no evidence of a connection between estrogens or NSAIDS and cognitive decline.

There is also not a consistent association involving cholesterol-lowering medicine, obesity, high blood pressure or blood homocysteine levels for either Alzheimer’s or cognitive decline.

state-of-the-science conference statement

Understanding dementia, from the Cleveland Clinic

May 25, 2010
Understanding dementia

New book examines the middle-aged brain

May 5, 2010

Barbara Strauch’s new book,”The Secret Life of the Grown-Up Brain” ($26.95, Viking) provides some good news about the state of human brains at middle age. They don’t necessarily deteriorate, and they in many ways improve with age.

By the time we hit our 40s, our brains have created connections and pathways over time, and Strauch–the health editor at The New York Times–says studies show how humans and animals function better if we have background knowledge, if we know something about a situation before encountering it.

“By middle age we’ve seen a lot. We’ve been there, done that,” she tells Tara Parker-Pope on the Times’ “Well” blog. “Our brains are primed to navigate the world better because they’ve been navigating the world better for longer.”

Is that fascinating, or what?

Parker-Pope asks Strauch (in a Q&A that’s worth reading in its entirety) what a middle-aged brain does better than a younger brain.

Her answer: “Inductive reasoning and problem solving — the logical use of your brain and actually getting to solutions. We get the gist of an argument better. We’re better at sizing up a situation and reaching a creative solution. They found social expertise peaks in middle age. That’s basically sorting out the world: are you a good guy or a bad guy? Harvard has studied how people make financial judgments. It peaks, and we get the best at it in middle age.”


An educational look at your brain

April 9, 2010

The Alzheimer’s Association offers this 16-slide educational tour of the brain.

It’s worth checking out.

How else would you know how much your brain weighs? (3 pounds.)

Or what percentage of your body’s fuel and oxygen your brain uses when you think hard? (Up to 50 percent.)

Or the chief type of cell that Alzheimer’s destroys? (Neurons, or nerve cells.) Turns out, the adult brain contains about 100 billion of these, with branches that connect at more than 100 trillion points. Scientists call this dense, branching network–pictured above–a “neuron forest.”


What is the hippocampus? And why should we care?

March 30, 2010
My Dad was dating the woman he would marry when the Lancet published research in 1985 about how “the decline of all higher cognitive functions in senile dementia of the Alzheimer type is attributable to histopathological changes in the hippocampal formation.”

Twenty-three years later, the year his wife got him settled into Silverado Senior Living, research still focused on the hippocampus, deep in the brain. It seems a larger hippocampus may protect people from the effects of Alzheimer’s disease-related brain changes, “an exciting area of research,” according to Professor Clive Ballard, director of research for the Alzheimer’s Society in London.

It’s not that any of this knowledge or experimentation could help my Dad now, or even back in 1985, that I find myself wondering about this structure, this region, this whatever-it-is piece of the brain. It’s the purple area in this drawing provided by Dr. Jim Phelps, an Oregon psychiatrist. This is a slice image, looking deep in the temporal lobe, which is above and infront of the ear on either side of the head.

He explains that the hippocampus–part of the innermost fold of the temporal lobe–is instrumental in helping us store memories. And, he gives three reasons why we should care about it:

1. This part of the brain appears to be absolutely necessary for making new memories. Alzheimer’s disease affects the hippocampus first and severely, which is why memory (or the ability to make new ones) is usually the first thing to start to falter in Alzheimer’s.

2. The hippocampus appears to shrink in severe mental illnesses, including severe depression and schizophrenia.

3. Estrogen has a direct effect on the hippocampus. Research on the role of estrogen in preventing Alzheimer’s is underway.

So this is what we know now. We can only imagine what we’ll know another 23 years from now.

ScienceDaily report from 2006 on the size of the hippocampus as it relates to Alzheimer’s disease

What is FTD?

March 9, 2010

We had never heard of FTD before (other than the flower delivery service) when a doctor gave our family the diagnosis for our patriarch of frontotemporal lobe dementia. He said it was like Alzheimer’s disease in some respects. But it was its own disease.

FTD actually refers to a group of rare neurological disorders that affect the frontal and temporal lobes of the brain, which control personality and social behavior, reasoning, movement, language, and some aspects of memory.

It often strikes people earlier than does Alzheimer’s, developing as early as 35, (but most are diagnosed in their 50s and 60s.)

Doctors say that FTD makes up about 3 percent of all dementia cases.

The FTD Support Forum lists some of the diseases that get classified as FTD include Pick’s Disease, FEDP-17, Supranuclear Palsy, Primary Progressive Aphasia and Corticobasal Degeneration.


It’s not Alzheimer’s

March 6, 2010

Frontotemporal dementia (frontotemporal lobar degeneration) is an umbrella term for a diverse group of uncommon disorders that primarily affect the frontal and temporal lobes of the brain, the areas generally associated with personality, behavior and language, according to the Mayo Clinic definition page.

Here’s what else it says:

In frontotemporal dementia, portions of the frontal and temporal lobes atrophy, or shrink. Signs and symptoms vary, depending upon the portion of the brain affected.

Some people with frontotemporal dementia undergo dramatic changes in their personality and become socially inappropriate, impulsive or emotionally blunted, while others lose the ability to use and understand language.

Frontotemporal dementia is often misdiagnosed as a psychiatric problem or as Alzheimer’s disease. But frontotemporal dementia tends to occur at a younger age than does Alzheimer’s disease, typically between the ages of 40 and 70.


Follow

Get every new post delivered to your Inbox.